Stay updated on Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe page footer was updated from “Revision: v3.5.0” to “Revision: v3.5.3,” reflecting a new ClinicalTrials.gov site/record display revision without changing the study details.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check37 days agoChange DetectedRevision: v3.5.0 is now displayed, replacing the previous Revision: v3.4.3.SummaryDifference0.1%

- Check52 days agoChange DetectedAdded revision note for v3.4.3 and removed the previous v3.4.2 revision.SummaryDifference0.1%

- Check73 days agoChange DetectedFallopian tube cancer was added to the Conditions section. A new page revision tag shows Revision: v3.4.2 (replacing v3.4.1).SummaryDifference0.1%

- Check81 days agoChange DetectedThe page now lists Primary Peritoneal Carcinoma and adds a resource link to the Genetic and Rare Diseases Information Center. The site revision updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check88 days agoChange DetectedGlossary toggle text added; metadata labels updated (Last Update Submitted that Met QC Criteria, No FEAR Act data) and Revision: v3.4.0, replacing the previous lowercase variants and Revision: v3.3.4.SummaryDifference0.2%

Stay in the know with updates to Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.